Related Experiment Video
Updated: Mar 15, 2026
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
Norepinephrine Transporter in Major Depressive Disorder: A PET Study
Sho Moriguchi1, Makiko Yamada1, Harumasa Takano1
1From the Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo; Decoding and Controlling Brain Information, Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama, Japan; and the Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo.
Major depressive disorder patients exhibit higher norepinephrine transporter availability in the thalamus. This elevated transporter availability is linked to improved attention, suggesting a role in major depressive disorder.
Area of Science:
- Neuroscience
- Psychiatry
Background:
- Norepinephrine transporter (NET) is implicated in major depressive disorder (MDD).
- NET availability and its clinical symptom correlations in MDD remain largely unknown.
Purpose of the Study:
- To investigate NET availability in the thalamus of MDD patients.
- To explore the association between NET availability and clinical symptoms in MDD.
Main Methods:
- Cross-sectional study involving 19 MDD patients and 19 healthy controls.
- Positron emission tomography (PET) scanning using (S,S)-[18F]FMeNER-D2 to measure NET availability.
- Quantification of NET availability in the thalamus using nondisplaceable binding potential (BPND).
Main Results:
- MDD patients showed significantly higher thalamic NET availability (BPND) compared to controls (29.0% increase).
- A specific thalamic subregion connected to the prefrontal cortex exhibited a 28.2% increase in NET availability.
- Elevated thalamic NET availability positively correlated with attention performance (Trail Making Test, Part A).
Conclusions:
- Findings indicate altered norepinephrine transmission in MDD patients.
- Altered thalamic NET availability may be associated with attention deficits in major depressive disorder.
Related Concept Videos
01:21Drugs Affecting Neurotransmitter Release or Uptake
01:23Antidepressant Drugs: MAOIs and Other Agents